Abstract
Purpose This analysis was undertaken to dosimetrically compare iridium-192 high-dose-rate brachytherapy (IB) and Xoft Axxent Electronic Brachytherapy (XB; Xoft Inc., Sunnyvale, CA) in the treatment of endometrial cancer. Methods and Materials The planning CT scans from 11 patients previously treated with IB were used to construct hypothetical treatment plans using the source characteristics of the XB device. The mean V 95, V 100, and V 150 (percent of the planning target volume that received 95%, 100%, and 150% of the prescription dose) were calculated. For both the bladder and rectum, the V 35 (percent of the organ that received 35% of the prescription dose) and V 50 (percent of the organ that received 50% of the prescription dose) were calculated for each patient using both methods of vaginal brachytherapy. Results The mean % V 95 was 99.7% vs. 99.6% ( p = ns) and the mean % V 100 was 99.0% vs. 99.1% ( p = ns) for the IB and XB methods, respectively. The mean % V 150 was 35.8% vs. 58.9% ( p < 0.05) for the IB and XB methods, respectively. The mean bladder % V 35 was 47.7% vs. 27.4% ( p < 0.05) and the mean bladder % V 50 was 26.5% vs. 15.9% ( p < 0.05) for the IB and XB methods, respectively. The mean rectal % V 35 was 48.3% vs. 28.3% ( p < 0.05) and the mean rectal % V 50 was 27.8% vs. 17.0% ( p < 0.05) for the IB and XB methods, respectively. Conclusions The IB and XB methods of vaginal brachytherapy offer equivalent target volume coverage; however, the XB method allows increased sparing of the bladder and rectum.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.